Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW)

被引：0
作者：
Shitara, Kohei
Xu, Rui-Hua
Moran, Diarmuid Martin
Guerrero, Abraham
Li, Ran
Pavese, Janet
Matsangou, Maria
Bhattacharya, Pranob P.
Ajani, Jaffer A.
Shah, Manish A.
机构：
[1] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[2] Sun Yat Sen Univ, Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[3] Astellas Pharma Global Dev Inc, Northbrook, IL USA
[4] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Gastrointestinal Med Oncol, Houston, TX USA
[5] Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4035
引用
收藏
页数：1
相关论文
共 50 条
  • [31] SPOTLIGHT: Phase 3 study of Zolbetuximab+mFOLFOX6 versus placebo+mFOLFOX6 in first-line claudin18.2+/HER2- advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
    Lordick, F.
    Shitara, K.
    Al-Batran, S. -E
    Bang, Y. -J
    Catenacci, D.
    Enzinger, P.
    Ilson, D.
    Kim, S.
    Shah, M. A.
    Van Cutsem, E.
    Xu, R. -H
    Arozullah, A.
    Park, J. W.
    Ajani, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 218 - 218
  • [32] Zolbetuximab plus CAPOX versus CAPOX in first-line treatment of claudin18.2+/HER2- advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study
    Shah, Manish A.
    Ajani, Jaffer A.
    Al-Batran, Salah-Eddin
    Bang, Yung-Jue
    Catenacci, Daniel V. T.
    Enzinger, Peter C.
    Ilson, David H.
    Kim, Sunnie S.
    Lordick, Florian
    Shitara, Kohei
    Van Cutsem, Eric
    Arozullah, Ahsan
    Raizer, Jeffrey J.
    Park, Jung Wook
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [33] SPOTLIGHT: Phase III study of zolbetuximab+mFOLFOX6 versus placebo+mFOLFOX6 in first-line Claudin18.2+/HER2- advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
    Shitara, K.
    Al-Batran, S-E.
    Bang, Y-J.
    Catenacci, D.
    Enzinger, P. C.
    Ilson, D. H.
    Kim, S.
    Lordick, F.
    Shah, M. A.
    van Cutsem, E.
    Xu, R-H.
    Arozullah, A.
    Park, J. W.
    Ajani, J. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1317 - S1317
  • [34] Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial (vol 401, pg 1655, 2023)
    Shitara, K.
    Lordick, F.
    Bang, Y-J
    LANCET, 2023, 402 (10398) : 290 - 290
  • [35] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
    Xu, Rui-hua
    Arkenau, Hendrik-Tobias
    Bang, Yung-Jue
    Denlinger, Crystal S.
    Kato, Ken
    Tabernero, Josep
    Wang, Jin
    Li, Jiang
    Castro, Henry
    Moehler, Markus H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [36] Phase II study of cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Pinto, C.
    Di Fabio, F.
    Barone, C.
    Siena, S.
    Falcone, A.
    Cascinu, S.
    Rojas, Llimpe F.
    Artale, S.
    Schinzari, G.
    Giaquinta, S.
    Mutri, V
    Martoni, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 9 - 9
  • [37] Patient reported outcomes (PRO) results from phase II MONO and FAST zolbetuximab (IMAB362) trials in patients with advanced CLDN18.2+gastric and gastroesophageal junction adenocarcinoma (GA/GEJA)
    Morlock, R.
    Krukas-Hampel, M. R.
    Tuereci, Oe.
    ANNALS OF ONCOLOGY, 2018, 29
  • [38] Efficacy and safety of ramucirumab (RAM) for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma across age subgroups in two global phase 3 trials.
    Muro, Kei
    Cho, Jae Yong
    Bodoky, Gyorgy
    Goswami, Chanchal
    Chao, Yee
    dos Santos, Lucas Vieira
    Shimada, Yasuhiro
    Topuzov, Eldar
    Van Cutsem, Eric
    Tabernero, Josep
    Zalcberg, John Raymond
    Chau, Ian
    Cheng, Rebecca
    Hsu, Yanzhi
    Emig, Michael
    Orlando, Mauro
    Wilke, Hansjochen
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [39] Safety and efficacy results from the phase I/IIa study of FG-M108 plus CAPOX as first-line (1L) treatment for patients with CLDN18.2+/HER2-locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
    Liu, Funan
    Gong, Jifang
    Jin, Zhaoyu
    Zhang, Miao
    Zhang, Shu
    Zhang, Yanqiao
    Liang, Xinjun
    Li, Yun
    Yang, Xiaochun
    Yang, Yaping
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Phase III study of first-line zolbetuximab plus CAPOX versus placebo plus CAPOX in Claudin 18.2+/HER2-advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW.
    Shah, Manish A.
    Ajani, Jaffer A.
    Al-Batran, Salah-Eddin
    Bang, Yung-Jue
    Catenacci, Daniel
    Enzinger, Peter C.
    Ilson, David H.
    Kim, Sunnie
    Lordick, Florian
    Shitara, Kohei
    Van Cutsem, Eric
    Arozullah, Ahsan
    Park, Jung Wook
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345